

Claims

1. Use of C-peptide in the manufacture of a medicament for administration to a patient as a once daily dose for the treatment of diabetes and/or diabetic complications.
2. A pharmaceutical composition comprising C-peptide together with at least one pharmaceutically acceptable carrier or excipient for administration to a patient as a once daily dose for the treatment of diabetes and/or diabetic complications.
3. Method of treating diabetes and/or diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient in a once daily dose.
4. Use, pharmaceutical composition or method according to any one of claims 1 to 3 wherein the C-peptide is human C-peptide.
5. Use, pharmaceutical composition or method according to any one of claims 1 to 4 wherein said C-peptide is the fragment EGSLQ (SEQ ID NO. 2).
6. Use, pharmaceutical composition or method according to any one of claims 1 to 5 wherein the patient is a human.
7. Use, pharmaceutical composition or method according to any one of claims 1 to 6 wherein the medicament contains 100 to 1800 nmol of C-peptide.